Hims & Hers runs an online clinic that mails treatments monthly
Online doctor visits
a licensed doctor or nurse writes the prescription in an app
Its own pharmacies
fill the order and mail it every month
2.79 million
subscribers in the US, Britain, Europe, Australia and Canada
People use it for things they would rather not raise with a family doctor, or that insurance will not pay for: hair loss, weight, skin, menopause and low testosterone.
The company · 2 · What exactly does it sell?
Most sales come from American subscribers
Each $1 of sales in Q3 2026, by where it was sold
74%26%
American subscribersClinics it bought abroad
At home it sells under the Hims and Hers brands. Abroad it bought online clinics in Britain, Australia and Canada. It reports no split by condition treated.
The company · 3 · How does it make money?
Customers pay every month until they cancel
$105paid by each subscriber a month in Q3 2026, against $81 a year earlier
57 centskept from each $1 after the drugs' cost, against 74 a year earlier
28 centsof each $1 of sales spent on marketing in Q3 2026
Billing is automatic each month, and a customer can cancel or pause between bills. Branded weight-loss drugs bring more money per customer but leave less of it behind.
Is it a good business? · 4 · What gives it an edge?
Two well-known brands and one app for many conditions
Hims and Hers
brands built with heavy advertising
13%
more subscribers than a year earlier
Someone who came for hair loss can add skin or weight care in the same app, so each subscriber pays more than a year ago.
Is it a good business? · 5 · What is the catch?
The drugs are not its own, and the makers sell them too
Lillysells the same weight-loss drugs to any patient at identical prices
Novo Nordisksued it over a patent in February 2026, then dropped the suit
A customer can cancel any month and buy the same branded drug elsewhere, so the platform cannot charge more for the drug itself.
Is it a good business? · 6 · What does its record show?
Sales grew sixteenfold, but profit never got far above zero
Sales, $B
0.3
0.5
0.9
1.5
2.3
2.9
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$148.8M → $2,347.6Mrevenue, 2020 to 2025
Best year4.5%official profit per $1 in 2025, its best year
Now-8.1%official profit per $1 over the past year
Revenue grew every year. Profit turned positive in 2024 and 2025, then fell to a loss after the switch to branded weight-loss drugs and the purchase of clinics abroad.
Is it a good business? · 7 · How much room is there to grow?
One in eight American adults takes a weight-loss drug
12%of US adults taking a GLP-1 drug in late 2025
About 17%of them got it from an online provider
$2.2BHims & Hers' US revenue in 2025, across every condition
Most people still get these drugs from their own doctor. Nobody outside measures how much is spent buying them online, so the market in dollars is unknown.
Is it a good business? · 8 · Who is in charge?
The co-founder runs it and controls the votes
Andrew Dudumco-founder, chief executive and chairman since 2021
87.73%of the votes, through shares carrying 175 votes each
2027the year his performance pay is measured on sales and management's profit
Outside shareholders cannot outvote him. His pay targets use management's own profit measure, which leaves pay in shares out.
The story right now · 9 · How much do weight-loss drugs matter here?
Weight-loss drugs are its biggest bet, made by two companies
Lilly, Novo Nordiskmake the weight-loss drugs the app now sells
March 2026when it stopped selling its own copies of them
During the shortages it made its own copies of these drugs at lower prices. Now it sells the makers' branded drugs at the makers' prices, which brings in more per customer but keeps less.
The story right now · 10 · Why did profit fall when sales rose?
Reselling a branded drug leaves less behind than making your own
It made its own copiesKept 74 cents of each $1 a year earlier.
It switched to branded drugsMarch 2026, at the makers' prices.
Each customer pays more$105 a month, up from $81.
It keeps less of each dollar57 cents in Q3 2026, and a loss.
The maker sets the price and takes most of it, so a bigger bill does not mean a bigger profit. Lilly charges any patient the same as it charges on this app.
The story right now · 11 · What changed lately?
Sales jumped on bought clinics while profit turned to a loss
49%revenue growth in Q3 2026, against 21% in the US alone
$135Mof Q3 2026 revenue from Eucalyptus, bought in June
$33.0Mlost in Q3 2026, against a profit a year earlier
Weak quarter
Lilly's drugs join the app this quarter, and management expects another quarter of fewer subscribers. The next report, around 22 February 2027, shows whether customers come back.
The story right now · 12 · What is everyone arguing about?
Can a reseller of branded drugs earn real profit?
Many investors think
A fast grower sold off too far
We think
A busy clinic that keeps little of each sale and owes more than it holds
Against us: if scale cuts marketing and pharmacy costs and official profit passes 8% of sales, the business could earn into today's price.
The price and our view · 13 · What is a share worth?
The price sits above even our sunny future
$4.23what we think a share is worth · the last close is of that
$4.23our value
Attractive below $3.38
Unattractive above $5.08
$1.41gloomy: growth half what analysts expect, thinner profit
$4.23our estimate: analysts' growth, profit back to its best
$16.05sunny: faster growth and profit twice its best year
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years, counting pay in shares as a cost and money owed as debt. Our rule: buy only at least a fifth below our estimate.
The price and our view · 14 · What if it all works?
As a bet on newer treatments, it is priced for success
Priced for successthe kind of bet this is
0.9×if it works
73%kept if it fails
Multiples of the company's value when the bet was last struck, 16 Nov 2026.
Valued alone, the established clinic covers less than today's price once its debts are paid, so success with testosterone and peptides adds little and failure costs a lot.
The price and our view · 15 · How could we be wrong?
Suppliers that compete, a lawsuit and money owed
The drug makersBiggest
Sell the same drugs directly.
The FTC lawsuitWatch
Over how subscriptions renew and cancel.
Money owedShowing now
About $1.2B more than its cash.
How many cancelUnknown
Not reported.
Rules on compounding, online prescribing and testosterone govern much of what it sells, and the founder controls the votes.
The price and our view · 16 · How will we know?
February's report shows whether customers come back
Subscribers growing again with Lilly's drugs on the appGood sign
Official profit passing 8% of salesGood sign
A 2027 profit forecast below 9% of sales on management's measureBad sign
FEB 202722
Fourth-quarter 2026 results, around 22 February 2027. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 17 · So, what do we think?
A fast-growing clinic at a price far above its worth
$4.23our value
Attractive below $3.38
Unattractive above $5.08
UnattractiveHigh conviction
Sales grow fast and each customer pays more, but it resells drugs the makers also sell, its best year earned little and it owes more than it holds. The price is about 439% of our value.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Hims & Hers lets people get treatment for things they would rather not raise with a family doctor, or that insurance will not pay for: hair loss, erectile problems, weight, skin, menopause, low testosterone. A customer answers questions in the app, a licensed doctor or nurse writes a prescription, and the company's own pharmacies mail it.
About 2.79 million people subscribe. Without it they would see their own doctor, buy from the drug maker's website, or use a rival app such as LifeMD or the private Ro.
How it makes money
Customers are billed automatically every month until they cancel or pause, and each paid about $105 a month in Q3 2026, up from $81 a year earlier as more bought weight-loss drugs. About three quarters of revenue comes from the United States and a quarter from clinics abroad. No one customer matters much.
Growth and profit
What growth costs
Until 2025 growth made the company more profitable: marketing and admin fell as a share of sales and official profit turned positive. Since then branded drugs and bought clinics have cut what it keeps from each sale, and over the past year it lost about 8 cents on each dollar.
Its record
The numbers
Is it growing?Fast
Sales grew 30% over the twelve months to Sep 2026, slower than the 59% in the year to Dec 2025.
Is it profitable?Losing
Operating margin is −8.1%, down from −3.4% in the year to Dec 2023.
Does growth pay off?Costly
Running costs take 72¢ of each sales dollar, down from 118¢ in the year to Dec 2021.
Does it earn good returns?Poor
Shareholders' money lost 41% a year, up from −115% in the year to Dec 2021.
Is it making cash?Thin
It turned 0.3% of sales into free cash, $8.22M over the last twelve months.
Is the balance sheet safe?Heavy debt
It owes $655M more than the cash it holds, about 3.6 years of the cash its operations bring in.
Are shares being diluted?Diluting
The share count rose 25% in 4.8 years, and pay in shares costs 6.2% of sales.
Why it wins
The evidence
Its edge is its two brands and one app for many conditions: someone who came for hair loss can add skin or weight care without searching again. Each subscriber pays more than a year ago, and marketing fell to 28% of revenue.
The weak spot is that the drugs are not its own. Lilly sells the same weight-loss drugs to any patient at the same prices, and a customer can cancel any month.
Who could beat it
The rivals in full
Lilly and Novo Nordisk, which make the weight-loss drugs, sell them to patients directly. Rival apps such as LifeMD and the private Ro offer the same care, and Amazon runs its own online clinic and pharmacy. A family doctor with insurance is still how most people get these drugs.
a customer gets an online visit and a prescription through Amazon
Family doctors and retail pharmaciesnot listed
a patient gets the prescription in person and fills it locally, often with insurance
How big it could get
The market and who has signed
The market
About one in eight American adults were taking a weight-loss or diabetes drug of this kind in late 2025, and about a sixth of them got it online. Hims & Hers' whole US business took in $2.2B in 2025.
Nobody outside publishes how much people spend on these drugs online, so the size of the market it sells into is not measured in dollars.
Who runs it
Leaders, pay and the cash
Who runs it
Andrew Dudum co-founded the company and has run it since it listed in 2021. Through special shares with 175 votes each he controls about 88% of the votes, so outside shareholders cannot outvote him.
His long-term pay rests on 2027 revenue and management's own profit measure, which leaves out stock pay.
The last report
The latest report
Hims & Hers grew revenue 49%, much of it bought, and lost money
What it did to the thesis Weak quarter
It weakened the business case: growth at home slowed, the margin fell sharply on branded drugs, and subscribers are expected to fall again. Revenue per subscriber rose, which helps, but nothing in it closes the gap between the price and our value.
The report
In Q3 2026, the quarter to September, revenue rose 49% to $890.4M, but US revenue rose 21% and about $135M came from Eucalyptus, bought in June. Subscribers rose 13% from a year earlier to 2.79 million.
The gross margin fell to 57% from 74% as branded drugs replaced the company's own, and it lost $33.0M. Management expects another quarter of fewer subscribers and guides a lower margin for the year.
What's happening now
The background
The shares fell 48.5% in a year while revenue per share rose 38%, so buyers now pay far less for each dollar of sales. Lilly's drugs join the app this quarter.
The next test is the fourth-quarter report, expected on 22 February 2027: whether subscribers grow again with both makers' drugs on offer, and what profit margin management guides for 2027.
Where we disagree
Both sides in full
The market
A fast grower sold off too far: most analysts rate it a hold, a third a buy.
We believe
A busy online clinic that keeps little of each sale and owes more than it holds, priced above our best case.
The argument
Most analysts rate it a hold after the fall and value it on management's profit measure. Counting stock pay as a cost and the acquisition payments as debt, even twice its best margin leaves our value below the price.
The evidence against us: if scale cuts marketing and pharmacy costs and official profit passes 8% of sales while growth stays above 20%, the business could earn into today's price.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and a 25% tax; any cash shortfall is raised in new shares at the price. The bridge adds cash and short-term investments and subtracts the convertible notes and the $563.1M still owed for Eucalyptus, which may be paid in shares; the earn-outs of $170.8M are left out.
The three cases
Bear case$1.41
Growth runs at half the analysts' path, 14%, 8% and 6%, the margin settles at 2.3%, the analysts' 2028 operating margin of 8.5% less stock pay near 6.2%, and new capital earns only the 8% rate: the test of a price war with the drug makers.
Our value$4.23
Revenue grows 29%, 16% and 12% over three years, the analysts' path (C26), then fades toward 4%, closing 30% of the gap each year; the margin moves from minus 8.1% to 4.5%, the best year it has filed (2025), with stock pay near 6% a cost and new capital earning only the 8% rate.
Bull case$16.05
Growth runs a quarter above the analysts' path, 36%, 20% and 15%, the margin reaches 10%, more than twice its best filed year of 4.5%, and new capital earns 11%: the test of scale cutting marketing and pharmacy costs.
The bet
Seen as a bet
This bet is on Hims & Hers' newer treatments: testosterone injections launched in October 2026, peptides launching in November and at-home blood tests. No revenue is filed for them.
Valued alone at what we think it deserves, the established platform covers less than today's price once the money owed is taken off, so part of the price already rests on the newer lines. If they reach the big win the shares gain little; if they fail, a lot is lost, which makes it a bet priced for success.
What could go wrong
Every risk
The risks
Suppliers that compete
Lilly and Novo make the drugs and sell them to patients directly at identical prices.
A government lawsuit
The FTC is suing over how subscriptions renew and cancel; a hearing is set for January 2027.
Rules on what it sells
Compounding, online prescribing and controlled-substance rules govern testosterone, peptides and more.
Money owed
Notes and payments for Eucalyptus exceed its cash by about $1.2B, and some may be paid in new shares.
One person decides
The founder controls about 88% of the votes, so outside owners cannot overrule him.
What we still do not know
How many subscribers cancel each month; the company does not say.
How much US weight loss earns now that it sells branded drugs, since no split by condition is filed.
Whether the FTC case forces changes to how the platform bills.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The shares fall back within 20% above what we think the business is worth.
→ Attractive
The shares fall to 80% of what we think the business is worth.
→ Neutral
Official operating profit passes 8% of sales over four quarters. Revenue growth over four quarters stays at 20% or more.
The next test
It supports the case if
Revenue at or above $895M, subscribers above 2.8M, a gross margin back near 60% and a 2027 guide with adjusted EBITDA at 9% of revenue or more.
It pressures the case if
Revenue below $875M, subscribers falling again, or a 2027 adjusted EBITDA guide below 9% of revenue.
We would also be wrong if
Subscribers fall for two more quarters after Lilly's drugs arrive.
The gross margin falls below 50% in a quarter of 2027.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
2 of 4
Financial position
2 of 4
Execution record
2 of 4
Per share capture
3 of 4
Potential
3 of 4
Risk profile
2 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits far above our value and above our bull case.
BusinessNegative
The brands draw customers, but the drugs are the makers' at the makers' prices and customers cancel monthly.
GrowthMixed
Revenue grows fast, but at home it has slowed and much of the rest was bought abroad.
RisksNegative
A government suit over subscriptions, compounding rules, suppliers that compete with it and a founder who controls the votes.
RivalsNegative
The drug makers offer their drugs directly, and private apps and Amazon offer the same care.
The groupMixed
It moves with the weight-loss drug trade, which grows fast but is set by two makers.
Latest newsMixed
The Lilly deal widens the shelf, but the last report cut the margin guide and subscribers fell.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.